News articles about Cara Therapeutics (NASDAQ:CARA) have been trending somewhat negative on Wednesday, according to Alpha One Sentiment Analysis. The research firm, a subsidiary of Accern, ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cara Therapeutics earned a news sentiment score of -0.03 on Alpha One’s scale. Alpha One also assigned news stories about Cara Therapeutics an impact score of 67 out of 100, indicating that recent news coverage is likely to have an impact on the company’s share price in the immediate future.
Here are some of the news stories that may have effected AlphaOne Sentiment Analysis’s rankings:
- Cara Therapeutics Inc (CARA) Receives Average Rating of “Buy” from Brokerages (americanbankingnews.com)
- Cara Therapeutics Inc (CARA) PT Raised to $22.00 (americanbankingnews.com)
- Insider Buying: Cara Therapeutics Inc (CARA) Major Shareholder Buys 500,000 Shares of Stock (americanbankingnews.com)
- Cara Therapeutics’ (CARA) “Positive” Rating Reaffirmed at Piper Jaffray Companies (americanbankingnews.com)
- Cara Therapeutics Inc CARA Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (bioportfolio.com)
A number of brokerages have issued reports on CARA. Janney Montgomery Scott lifted their price target on shares of Cara Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a report on Wednesday, March 29th. Vetr upgraded shares of Cara Therapeutics from a “strong sell” rating to a “sell” rating and set a $17.31 price target on the stock in a report on Thursday, March 30th. Piper Jaffray Companies reiterated a “positive” rating and issued a $23.00 price target on shares of Cara Therapeutics in a report on Tuesday, March 28th. Laidlaw reiterated a “buy” rating and issued a $35.00 price target (up from $20.00) on shares of Cara Therapeutics in a report on Tuesday, March 28th. Finally, Needham & Company LLC reiterated a “positive” rating and issued a $23.00 price target on shares of Cara Therapeutics in a report on Tuesday, March 28th. One analyst has rated the stock with a sell rating and ten have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $24.50.
Shares of Cara Therapeutics (NASDAQ:CARA) traded up 0.92% during trading on Wednesday, hitting $17.58. 2,423,234 shares of the company’s stock were exchanged. The company has a 50-day moving average of $16.45 and a 200-day moving average of $11.64. Cara Therapeutics has a 12-month low of $4.35 and a 12-month high of $20.90. The company’s market cap is $479.99 million.
In other Cara Therapeutics news, major shareholder Ventures Vi Lp Rho acquired 500,000 shares of the company’s stock in a transaction dated Friday, March 31st. The shares were acquired at an average cost of $18.19 per share, with a total value of $9,095,000.00. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 7.70% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This piece was first posted by sleekmoney and is the property of of sleekmoney. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://sleekmoney.com/cara-therapeutics-cara-receiving-somewhat-negative-press-coverage-alphaone-reports/1726998.html.
About Cara Therapeutics
Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the body’s peripheral nervous system.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/cara-therapeutics-cara-receiving-somewhat-negative-press-coverage-alphaone-reports/1726998.html
Receive News & Ratings for Cara Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.